Rapport Therapeutics to Host 2025 Investor and Analyst Day
BOSTON and SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated...
Neurology
ESOC 2025: Combined oral contraceptives triple risk of cryptogenic stroke in young women, new study shows
HELSINKI, May 20, 2025 /PRNewswire/ -- New research presented today at the European Stroke Organisation Conference (ESOC) 2025 revealed that...
Natus announces entry into Point-of-Care EEG with launch of BrainWatch
MIDDLETON, Wis., May 20, 2025 /PRNewswire/ -- Natus Medical Incorporated has announced the official launch of BrainWatch™, the highly anticipated...
McFarland Clinic Taps Nabla to Support Clinicians and Streamline Documentation in Epic
Following a successful pilot, Nabla is now used across 12 specialties at McFarland Clinic to help clinicians spend less time on...
Phase II Data in Treatment-Naïve Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Demonstrates Best-in-Class Efficacy as Monotherapy
--- Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). Paroxysmal Nocturnal Hemoglobinuria...
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through...
AI In Diagnostics Market to Hit $5.44 Billion by 2030 at CAGR 22.46% – Grand View Research, Inc.
SAN FRANCISCO, May 14, 2025 /PRNewswire/ -- The global artificial intelligence in diagnostics market size is expected to reach USD 5.44...
TeleSpecialists Achieves Perfect NCQA Reaccreditation Score, Setting New Standard in Telemedicine Excellence
Accomplishment highlights the company's commitment to quality, excellence in credentialing, and ongoing advancements in patient care FORT MYERS, Fla., May...
Epilepsy Foundation of America to Present Lifetime Accelerator Award to Orrin Devinsky, M.D.
Renowned Neurologist and Epilepsy Advocate Honored for Decades of Innovation in Therapeutics, Research, and Patient Care BOWIE, Md., May 14,...
PhaseV Lands $50M Series A to Supercharge AI for Clinical Development, Backed by Top VCs and Trusted by Leading Pharma Clients
With a Growing List of 30+ Global Customers, Including Top Pharma, PhaseV is Poised to Transform Clinical Development at Scale...
Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer
— Dr. Binks joins Capricor in anticipation of potential approval of deramiocel in Q3 2025, bringing extensive experience in neuromuscular...
Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101
- BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model - - The DBA/2 model is...
Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data
HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader...
Critical Path Institute Celebrates 20 Years of Advancing Drug Development through Innovation and Collaboration
TUCSON, Ariz., May 8, 2025 /PRNewswire/ -- The year 2025 marks a historic milestone for Critical Path Institute® (C-Path), as the...
Zilia Closes Bridge Round with Participation from Existing and New Investors Including Linearis Ventures
QUEBEC CITY, May 7, 2025 /PRNewswire/ - Zilia Inc. (''Zilia''), a medical technology company pioneering the use of the eye...
Pramana Strengthens Scientific Leadership with Addition of Dr. Adrian Noriega to Advance Neurodegenerative Pipeline
VANCOUVER, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Pramana Pharmaceuticals, a late-stage preclinical biopharmaceutical company developing a transformative small...
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
ATH434 Phase 2 Data to be Presented at Opening Plenary SessionMELBOURNE, Australia and SAN FRANCISCO, May 07, 2025 (GLOBE NEWSWIRE)...
Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights
Clene preparing for upcoming meeting in the second quarter with the U.S. Food and Drug Administration (FDA) to reach agreement...
Clario Announces Completion of Acquisition of WCG’s eCOA Business
Clario strengthens its leadership in digital endpoint data collection with the acquisition of WCG's eCOA business, enhancing support for neuroscience...
Lundbeck joins forces with Danish Centre for AI Innovation to improve brain health by advancing drug discovery with Gefion AI supercomputer
VALBY, Denmark, May 6, 2025 /PRNewswire/ -- H. Lundbeck A/S is pleased to announce its agreement with the Danish Centre for AI...